The data are growing that COVID booster jabs enhance protection — but their durability, impact and ability to quash the new variant are unknown
“Our immune response to these vaccines is really robust if you are healthy. Barring any massive surprise variants, I don’t see any reason why we’d need to get a fourth dose,” Ellebedy toldThe new variant could change the immunological picture. Among Omicron’s many mutations, few seem likely to compromise T cells’ ability to recognize the virus and attack infected cells, notes Alessandro Sette, a vaccine biologist at the La Jolla Institute for Immunology in California.
If they don’t, however, vaccine makers have a back-up plan: at least four companies have started developing Omicron-specific booster candidates. It will take months before any of those come to market, so public-health agencies continue to recommend standard boosters for the time being.Will boosters help to curb the pandemic?
“We are not yet seeing any reduction in the effectiveness of the boosters,” says Dvir Aran, a biomedical data scientist at the Technion — Israel Institute of Technology in Haifa.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Covid-19 news: Ministers plan for UK to ‘live with covid’Today’s covid-19 news: · UK ministers plan for nation to ‘live with covid’ · Novak Djokovic released from detention, but may have Australia visa cancelled · Mixed signals as to whether free lateral flow tests will be phased out in England
Weiterlesen »
Los Angeles Passes 2 Million Total Covid Cases Since Start Of Pandemic; Omicron Surge ContinuesWith infections still surging, Los Angeles County’s cumulative number of Covid cases throughout the pandemic surpassed the 2 million mark today, with 43,582 new cases confirmed. Those new cas…
Weiterlesen »
Avacta pauses sales of COVID-19 antigen test to boost Omicron sensitivityBritish biotech firm Avacta Group said on Monday it was halting sales of its COVID-19 antigen lateral flow test, AffiDX, to replace antibodies in the device and boost its ability to detect the Omicron coronavirus variant at lower viral loads.
Weiterlesen »
Avacta pauses sales of COVID-19 antigen test to improve Omicron sensitivityBritain's Avacta Group is halting sales of its COVID-19 rapid antigen lateral flow test to replace antibodies in the device and boost its ability to detect the Omicron variant, the biotech firm said on Monday, sending its shares plunging nearly 27%.
Weiterlesen »
New COVID-19 cases and hospitalizations are rising as the omicron surge continuesThe U.S. is still weeks away from a peak in the number of new COVID-19 cases as the country continues to report soaring rates of new infections.
Weiterlesen »
U.S. Covid-19 Cases Set to Triple Pre-Omicron RecordThe seven-day average of newly reported Covid-19 infections in the U.S. is on track to triple the pre-Omicron record set a year ago, when America saw a quarter million daily cases.
Weiterlesen »